68Ga-R10602 Imaging for Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you are starting a new line of therapy that includes certain drugs, you must be imaged while on single-agent endocrine therapy before starting any targeted therapy.
What data supports the effectiveness of the treatment 68Ga-R10602 for breast cancer?
The use of 68Ga in imaging has shown promise in detecting and managing various cancers, including breast cancer, by providing detailed images that help in diagnosing and planning treatment. Similar 68Ga-based imaging agents have been effective in visualizing tumors and metastases, suggesting potential for 68Ga-R10602 in breast cancer imaging.12345
Is 68Ga-R10602 safe for use in humans?
How is the drug 68Ga-R10602 different from other breast cancer treatments?
68Ga-R10602 is unique because it uses gallium-68, a radionuclide, for imaging in positron emission tomography (PET), which can provide higher-resolution images compared to traditional imaging agents. This approach helps in better visualization and management of breast cancer, especially in cases with suspected metastases.12456
What is the purpose of this trial?
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Eligibility Criteria
This trial is for adults with hormone-receptor positive breast cancer that's either locally recurrent or metastatic and not removable by surgery. Participants must have tried at least one endocrine therapy, have good liver and kidney function, a measurable tumor, and agree to use contraception. Exclusions include recent major surgery, radionuclide treatment, acute illness, unstable heart conditions, active infections like HIV or hepatitis B/C.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of 68Ga-R10602 followed by imaging and blood dosimetry
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 68Ga-R10602
Find a Clinic Near You
Who Is Running the Clinical Trial?
Radionetics Oncology
Lead Sponsor